What are the potential benefits of temporarily suspending RAAS inhibitors in hospitalized COVID-19 patients?
Potential benefits of temporarily suspending RAAS inhibitors in hospitalized COVID-19 patients may include a decreased risk of developing acute kidney injury and improved clinical outcomes in those with existing kidney dysfunction. Additionally, research has found that suspending RAAS inhibitors may be associated with a decreased risk of needing invasive ventilation or death. The ACC Expert Consensus Decision Pathway suggests that temporarily suspending RAAS inhibitors in hospitalized COVID-19 patients may be beneficial, but further research is needed to determine if this is the case.  